Chronic Leukemia Flashcards
philadelphia chromosome
excession mature neutrophil production
t(9;22) promotes fusion of 2 genes, BCR-ABL. protein p210 ->upregulated TK activity->promotes continuous cell cycling, inh apoptosis, inc mature neutrophil proliferation
CML - hematologic response
nml peripheral, WBC <450k, no immature cells
CML - cytogenetic response
complete: BMBx 0% Ph+ cells
partial: BMBx 1-34% Ph+ cells
Major = CR +PR
Minor = 35-95% Ph+ cells
CML - molecular response
complete: negative BCR-ABL by RT-PCR
major: cytogenetic remission with 3 log or greater reduction in BCR-ABL by RT-PCR
CML - tx goals
#1 maintain chronic phase - sustained cytogentic / molecular remission #2 prevent progression to accelerate/ blast #3 minimize toxicity of chronic tx #4 cure (only proven alloHSCT) #4 if accelerated/blast - induce 2nd chronic phase
CML - imatinib - phase III iris trial
1st trial - 100% hematologic response
yr 4,5,6,7,8 tox is less than tx during yr 1,2,3 (paradigm shift)
8yr OS: 85% (if CML related OS: 93%)
imatanib AE’s
hematologic (neutropenia, anemia, thrombocytopenia), LFTs
CML - nilotinib vs imatinib
24 mo MMR (primary): 71% N 300bid, 66% N 400bid, 44% I 400qd
12 mo CCyR: 87%, 85%, 77%
Progression to AP/BC: <1%, 1.8%, 4.6%
nilotinib 300mg bid AE’s
neutropenia (12%), thrombocytopenia (10%), anemia (3%), Rash (1%), t bili (4%), ALT (4%), AST (1%), lipase (6%), dec phos (5%)
CML - dasatinib vs imatinib
24 mo CCyR: 86% d 100qd vs 82% i 400qd
24 mo MMR: 64 vs 46%
CML - bosutinib vs imatinib
12 mo CCyR: 70 b vs 68 i%
12 mo MMR: 41 vs 27%
dz progression: 3 vs 10%
imatinib ADME keys
400mg qd
take with food
inhibits 3A4 / 2D6
metabolism: 3A4
dasatinib ADME keys
100mg qd
with or without food (avoid acid reducers)
metabolism: maybe 3A4
nilotinib ADME keys
300mg bid empty stomach metabolism 3A4 inhibits 3A4, 2C8, 2C9, 2D6 induces 2B6, 2C8, 2C9
bosutinib ADME keys
500mg daily
take with food
metabolism: 3A, P-gp
ponatinib ADME keys
45md daily
with or without food
metabolism: 3A, P-gp
mechanisms of resistance to TKI’s
#1 bcr-abl gene amplification / overexpression #2 mutation in the kinase domain (cell growth dependent of bcr-abl for 1 and 2) #3 secondary genetic alterations (cell growth independent of bcr-abl activity, clonal evolution)
TKI point mutations
T315I R to imatinib, dasatinib, nilotinib
CML - 2nd line tx
#1 dose escalation of i #2 2nd gen TKI (d, n, b) #3 3rd gen TKI (p) #4 omacetaxine #5 alloHSCT #6 clinical trial
CML - 2nd line dasatinib (data very similar for nilotinib)
chronic phase: 91% CHemR, 49% CCyR, 59% major CyR
accelerated phase: 63, 24, 34
blast crisis: 35, 32, 39
CML - salvage - 2 prior TKI’s - bosutinib
28.5mo median f/u: CHemR 73%, CCyR 24%, MMR 15%
CML - ponatinib - phase I - T315I mutation (made NEJM)
CHemR 100%, MCyR 92%, CCyR 75%, MMR 67%
CML - ponatinib - phase II
majorCyR 70%
CML - salvage - omacetaxine - T315I mutation
1.25 mg/m2 subQ bid x14day each 28day cycle (maintenace 7 day q28d)
CHR 77%, MajCyR 23%, CCyR 16%
median PFS 7.7 mo
omacetaxine ADRs
gIII/IV
thrombocyto 76%, neutrop 44%, anemia 39%, pancytop 21%, leukop18%, infx 8%, fatigue 5%
CML -salvage- omacetaxine - 2 prior TKIs
CP: OS 34 mo, MCyR 20%, CCyR 10%, CHR 69%
AP: 16 mo, 27, 0, 24%
CML - AP tx
#1 imatinib or other TKI (less response than if in chronic phase) #2 alloHSCT (much less common)
CML - blast crisis tx
#1 disappointing results with TKI's #2 induction chemo and/or TKI then alloHSCT: VAC CR 58%, OS 7mo, hyperCVAD #3 lymphoid blast more responsive than myeloid #4 consider alloHSCT if 2nd chronic phase
CML - NCCN - 1st line
may use any TKI except ponatinib
CLL: monoclonal B-cell
monoclonal b-cell detectable several yrs prior to CLL dx, similar antigen phenotype to CLL, 41 of 45pt had this screening positive
CLL: cytogenetics - poor risk (these effect initial regimen selection)
del 11q (OS: 79 mo), del 17p (OS: 32 mo)
CLL: somatic point mutations
TP53 15%, MYD88 10%, ATM 9%, NOTCH1 4%, etc, ect, ect
CLL: dz course
indolent, OS 1-20 yrs, OS dependent on stage of dz (Rai stage IV 3-4 yrs), richter’s transformation (<5%)
CLL: goals of tx
#1 reserved for stage III-IV or those with clinical sx #2 cytogenetics #3 age
CLL: front line without del 11q or del 17p
age >70: generally one/two drug, lighter chemo
chlorabm+/-R, BR, Cyclophos+pred+/-R, alemtuz, Flu+/-R, R, cladribine, lenalid
age <70: FCR, FR, PCR, BR
CLL: second line without del 11q or del 17p: if short response 18-36 mo
age >70: reduced dose FCR or PCR, BR, mpR, chloramb+/-R, ofat, alemtuzR, dose dense R
age <70: FCR, PCR, BR, RCHOP, RhyperCVAD, RdaEPOCH, OFAR, ofat, alemtuzR, mpR
CLL: 1st line: elderly, frail
chlorambucil +/- rituximab
rituximab
pulse steroids
CLL: FCR
fludarabine 25mg/m2 x3d
cyclophos 250mg/m2 x3d
ritux 375mg/m2 wk1 then 500mg/m2
q28d x6 cycles
CLL: FCR vs FC - front line
PFS: 51.8 vs 32.8 mo
CR: 44 vs 22
OS at 3yr: 87 vs 83
even thought CLL cells are not bound well by rituximab
CLL: bendamustine 100mg/m2 d1-2 vs chlorambucil d1-15 - front line
CR 31 vs 2
RR 68 vs 31
median PFS: 21.6 vs 8.3 mos
CLL: bendamustine 90mg/m2 d1-2 +ritux - front line
RR: 88 CR: 23 median EFS: 34 mo 27 mo OS: 91% centers moving toward this regimen from fludarabine for front line
CLL: bendamustine ADR
leukop 30, thromboc 22, neutrop 20, anemia 20, allergic rxn 2, infx 2
CLL: del 17p - 1st line
FCR, FR, alemtuz+/-R
CLL: del 17p - 2nd line
R-CHOP, R-hyperCVAD, ofatumumab, mpR, alemtuzumabR
CLL: del 11q : age <70 1st line
FCR, BR, PCR
CLL: del 11q : age >70 1st line
reduced dose FCR, BR, chlorambucil +/-R, cyclophos +pred +/-R, alemtuz, R, lenalidomide
CLL: del 11q : age <70 2nd line
FCR, PCR, BR, flu+alemtuz, RCHOP, RhyperCVAD, RdaEPOCH, OFAR, alemR, lenalidR, ofatumumab, mpR
CLL: del 11q : age >70 2nd line
reduced dose FCR, reduced dose PCR, BR, mpR, chlorambucilR, alemR, lenalidR, ofatumumab, R
CLL: relapsed CLL: FCR vs FC
PFS 30.6 vs 20.6mo
OS not reached vs 52 mo
RR 70 vs 58
CLL: relapsed CLL: bendamustine-R
RR 59%
CR 9%
OS 34mo
CLL: relapsed CLL: ofatumumab (third line)
RR 47%
median PFS 5.5mo
median OS 16.3mo
ofatumumab MOA
binds to CD20 at a different epitope than rituximab (binds better in CLL cells than rituximab); more infusion rxn’s than ritux
CLL supportive care - recurrent infxs
#antimicrobials as appropriate #IVIG is IgG 500
CLL supportive care - antibiotic px
give if purine analogue or alemtuzumab
HSV, PJP
for alemtuz CMV monitoring OR valganciclovir for 2 months after (gancic if viral load inc)
CLL supportive care - autoimmune cytopenias
AIHA, fludarabine associated AIHA (stop, tx, avoid subsequent flu), ITP (eval BMBx for causes, tx: steroids, ritux, ivig, csa, splenectomy, eltrom, romiplos), pure red blood cell aplasia (eval parvovirus B19)
CLL supportive care - immunizations
influenza q1yr, pneumococcal q5yr, avoid ALL live vaccines including herpes zoster
CLL supportive care - blood pdt support
irradiate all blood pdts, follow institutional guideline
CLL supportive care - TLS
std precautions
CLL supportive care - thromboprophylaxis
if lenalidomide: ASA 81mg if plts >50k
CLL supportive care - tumor flare rxns
for lenalidomide pts #painful lymph node enlargement (local inflammation at tx initiation), also could be spleen enlargement, low-grade fever, rash #tx: steroids (pred 25-50 qd x5-10d, antihistamines for rash or pruritis #px: in bulky LN >5cm pred 20mg qd x5-7d with rapid taper
CLL: OFAR regimen
oxaliplatin 25mg/m2 d1-4, fludarabine 30mg/m2 d2-3, cytarabine 1gm/m2 d2-3, rituximab d3 1st cycle then d1
q4wks x6